Xilio Therapeutics (XLO) Share-based Compensation (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Share-based Compensation data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 44.04% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 24.1% YoY), and the FY2025 full-year result was $11.0 million, up 50.68% from the prior year.
• Share-based Compensation retreated to $2.2 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.9 million in Q4 2025 to a low of $1.1 million in Q3 2025.
• A 5-year average of $1.8 million and a median of $1.8 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 170.36% in 2022 and slumped 33.55% in 2023, its largest moves.
• Tracing XLO's Share-based Compensation over 5 years: stood at $1.8 million in 2022, then climbed by 6.34% to $1.9 million in 2023, then dropped by 21.45% to $1.5 million in 2024, then jumped by 93.27% to $2.9 million in 2025, then declined by 24.54% to $2.2 million in 2026.
• Business Quant data shows XLO's Share-based Compensation at $2.2 million in Q1 2026, $2.9 million in Q4 2025, and $1.1 million in Q3 2025.